Specifically, we tested five ACE variants in the binding pocket for ACEis, which most guidelines recommend as the first-line treatment for the management of hypertension, seven tubulin variants (TUBB1) in the binding site of the polymerization inhibitor eribulin, and seven variants in the cholinesterase (BCHE)–binding site for the anti–Alzheimer’s disease (AD) medications tacrine and rivastigmine. Here, TUBB1 is linked to Alzheimer disease.